Latest Oncotype DX Stories
Agreement Marks Important Milestone in Delivering Personalized Medicine to More Breast Cancer Patients Worldwide REDWOOD CITY, Calif., Feb.
A new study published in The Oncologist details a novel approach to identifying patients with stage II colorectal cancer who are most likely to benefit from additional treatment due to a high
REDWOOD CITY, Calif., Feb. 3, 2015 /PRNewswire/ -- Genomic Health, Inc.
- Plans to Secure CE Mark for a European Launch of the Non-Invasive Test and Submit a Pre-IDE to the U.S. FDA in 2015 - TEL-AVIV, Israel, Feb.
REDWOOD CITY, Calif., Jan. 5, 2015 /PRNewswire/ -- Genomic Health, Inc.
Positive Results of Largest Genomic Study in DCIS Reconfirm Oncotype DX is a Strong, Independent Predictor of Local Recurrence SAN ANTONIO, Dec.
Presentations at SABCS and SUO Reveal Company's Ability to Detect Breast and Bladder Cancers in Blood and Urine, Respectively SAN ANTONIO, Dec.
Studies Presented at the 2014 Society of Urologic Oncology Annual Meeting Demonstrate Test's Value to Physicians and Patients, Support Increased Adoption and Reimbursement REDWOOD
Test Tailors Cancer Treatment Plan, Improves Outcomes and Lowers Chemo Costs Franklin, Tennessee (PRWEB) December 02, 2014 DiaTech Oncology, provider
Landmark Study Reconfirms Oncotype DX® Stratifies DCIS Patient Risk REDWOOD CITY, Calif., Dec. 2, 2014 /PRNewswire/ -- Genomic Health, Inc.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.